Jim Cramer has always had the goal of alerting investors when an incredible opportunity reveals itself. He knows how to spot the stocks that keep heading higher without any end in sight.
For instance, the $2.3 billion drug developer Esperion Therapeutics has been on a tear lately as investors anticipate its pill that is designed to lower levels of bad cholesterol in patients who are unable to take traditional statins.
The stock more than tripled last year, and then on Tuesday the company announced promising phase 2 data for its anti-cholesterol pill that sent it to $99 from $77.
"At that point you might have thought that the run was finished, especially since Esperion announced a 1.75 million share secondary offering on Tuesday night. But you would have been wrong," the "Mad Money" host said.
The secondary deal offered $100 per share, and considering that it closed at $110 on Thursday investors could have made a killing already.
Could this stock head even higher in 2015? To find out, Cramer spoke with Esperion CEO Tim Mayleben.